Calcium dobesilate
Calcium dobesilate is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
156 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular edema | D008269 | — | 5 | 3 | 15 | 7 | 30 | ||
| Cataract | D002386 | EFO_0001059 | H26.9 | — | — | 3 | 10 | 4 | 17 |
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | — | — | 1 | 3 | 2 | 6 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | 2 | — | 4 | — | 6 | |
| Postoperative pain | D010149 | G89.18 | — | — | — | 4 | 2 | 6 | |
| Inflammation | D007249 | — | — | — | 3 | 2 | 5 | ||
| Dry eye syndromes | D015352 | H04.12 | — | — | — | 4 | 1 | 5 | |
| Corneal edema | D015715 | EFO_1000879 | H18.20 | — | — | — | 2 | 1 | 3 |
| Retinal detachment | D012163 | EFO_0005773 | H33.2 | 1 | — | — | 2 | — | 3 |
| Replacement arthroplasty knee | D019645 | — | 2 | — | 1 | — | 3 |
Show 32 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | C90.0 | 2 | 1 | 1 | — | — | 4 | |
| Lymphoma | D008223 | C85.9 | 1 | 2 | 1 | — | — | 4 | |
| Infertility | D007246 | EFO_0000545 | — | 2 | 2 | — | 1 | 3 | |
| Neoplasms | D009369 | C80 | — | 1 | 1 | — | — | 2 | |
| Leukemia | D007938 | C95 | — | 1 | 1 | — | — | 2 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | — | — | 1 | — | — | 1 | |
| Tinea | D014005 | EFO_0007510 | B35.4 | — | — | 1 | — | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | 1 | — | — | 1 |
| Neuroblastoma | D009447 | EFO_0000621 | — | — | 1 | — | — | 1 | |
| Opsoclonus-myoclonus syndrome | D053578 | EFO_1001383 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | C85.9 | — | 2 | — | — | — | 2 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | — | 2 | — | — | — | 2 | |
| Hodgkin disease | D006689 | C81 | — | 2 | — | — | — | 2 | |
| B-cell lymphoma | D016393 | — | 1 | — | — | — | 1 | ||
| Uveal neoplasms | D014604 | EFO_1001230 | — | 1 | — | — | — | 1 | |
| Wet macular degeneration | D057135 | EFO_0004683 | — | 1 | — | — | — | 1 | |
| Pseudophakia | D019591 | — | 1 | — | — | — | 1 | ||
| Fuchs' endothelial dystrophy | D005642 | EFO_0003946 | H18.51 | — | 1 | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
Show 9 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Plasmacytoma | D010954 | C90.3 | 1 | — | — | — | — | 1 | |
| Lacrimal apparatus diseases | D007766 | HP_0009926 | H04 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 | ||
| T-cell lymphoma | D016399 | 1 | — | — | — | — | 1 | ||
| Retinal telangiectasis | D058456 | Orphanet_190 | H35.02 | 1 | — | — | — | — | 1 |
| Retinal perforations | D012167 | EFO_1001028 | 1 | — | — | — | — | 1 | |
| Type 1 stickler syndrome | C537492 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory sounds | D012135 | HP_0010307 | R06.1 | — | — | — | — | 1 | 1 |
| Pruritus | D011537 | HP_0000989 | L29 | — | — | — | — | 1 | 1 |
| Cesarean section | D002585 | — | — | — | — | 1 | 1 | ||
| Hypertrophic cicatrix | D017439 | L91.0 | — | — | — | — | 1 | 1 | |
| Cicatrix | D002921 | HP_0100699 | L90.5 | — | — | — | — | 1 | 1 |
| Keloid | D007627 | EFO_0004212 | L91.0 | — | — | — | — | 1 | 1 |
| Newborn respiratory distress syndrome | D012127 | P22 | — | — | — | — | 1 | 1 | |
| Deglutition disorders | D003680 | HP_0002015 | R13.1 | — | — | — | — | 1 | 1 |
| Thyroidectomy | D013965 | — | — | — | — | 1 | 1 | ||
| Fibrosis | D005355 | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CALCIUM DOBESILATE |
| INN | calcium dobesilate |
| Description | Calcium dobesilate is a vasoprotective. It is the calcium salt of dobesilic acid.
It is a synthetic molecule with the ability to reduce capillary permeability in the body. In Switzerland the drug is sold by the pharmaceutical company OM Pharma under the trade name of Doxium in capsules containing 500 mg of active ingredient.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=S(=O)([O-])c1cc(O)ccc1O.O=S(=O)([O-])c1cc(O)ccc1O.[Ca+2] |
Identifiers
| PDB | — |
| CAS-ID | 20123-80-2 |
| RxCUI | 1904 |
| ChEMBL ID | CHEMBL2106191 |
| ChEBI ID | — |
| PubChem CID | 29963 |
| DrugBank | — |
| UNII ID | 5921X1560Q (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 409 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
33 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more